BeOne Medicines (STU:IJ0) Cyclically Adjusted Book per Share: €1.86 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IJ0 BeOne Medicines Ltd STU:IJ0
83 GF Score
Price €20.57
GF Value €24.51
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Cyclically Adjusted Book per Share?

BeOne Medicines STU:IJ0 -2.30% 83 Cyclically Adjusted Book per Share is €1.86 as of Mar. 2026. GuruFocus rates STU:IJ0 with a GF Score™ of 83/100 and a GF Value™ of €24.51 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BeOne Medicines's adjusted book value per share for the three months ended in Mar. 2026 was €2.850. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.86 for the trailing ten years ended in Mar. 2026.

During the past 12 months, BeOne Medicines's average Cyclically Adjusted Book Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-18), BeOne Medicines's current stock price is €20.565. BeOne Medicines's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €1.86. BeOne Medicines's Cyclically Adjusted PB Ratio of today is 11.06.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BeOne Medicines was 11.92. The lowest was 4.78. And the median was 8.53.


BeOne Medicines  (STU:IJ0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BeOne Medicines's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=20.565/1.86
=11.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BeOne Medicines was 11.92. The lowest was 4.78. And the median was 8.53.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BeOne Medicines Cyclically Adjusted Book per Share Related Terms


BeOne Medicines Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Cyclically Adjusted Book per Share Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 2.09 1.75

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.02 2.08 1.52 1.75 1.86

STU:IJ0 vs MRNA, RPRX, ROIV: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, BeOne Medicines's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Cyclically Adjusted PB Ratio falls into.


STU:IJ0
83GF Score
BeOne Medicines Ltd STU:IJ0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BeOne Medicines's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.85/108.0600*108.0600
=2.850

Current CPI (Mar. 2026) = 108.0600.

BeOne Medicines Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.458 100.088 0.494
201609 0.391 99.604 0.424
201612 0.649 99.380 0.706
201703 0.556 100.040 0.601
201706 0.439 100.285 0.473
201709 1.067 100.254 1.150
201712 0.956 100.213 1.031
201803 1.560 100.836 1.672
201806 1.480 101.435 1.577
201809 2.190 101.246 2.337
201812 1.974 100.906 2.114
201903 1.833 101.571 1.950
201906 1.753 102.044 1.856
201909 1.480 101.396 1.577
201912 1.081 101.063 1.156
202003 2.525 101.048 2.700
202006 2.219 100.743 2.380
202009 3.077 100.585 3.306
202012 2.671 100.241 2.879
202103 2.809 100.800 3.011
202106 2.485 101.352 2.649
202109 2.352 101.533 2.503
202112 4.066 101.776 4.317
202203 4.004 103.205 4.192
202206 3.717 104.783 3.833
202209 3.484 104.835 3.591
202212 3.051 104.666 3.150
202303 2.850 106.245 2.899
202306 2.557 106.576 2.593
202309 2.606 106.570 2.642
202312 2.394 106.461 2.430
202403 2.276 107.355 2.291
202406 2.273 107.991 2.274
202409 2.243 107.468 2.255
202412 2.298 107.128 2.318
202503 2.307 107.722 2.314
202506 2.291 108.075 2.291
202509 2.446 107.710 2.454
202512 2.584 107.200 2.605
202603 2.850 108.060 2.850

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €1.86 mean?
BeOne Medicines (STU:IJ0) has a Cyclically Adjusted Book per Share of €1.86 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Cyclically Adjusted Book per Share too high?
BeOne Medicines' current Cyclically Adjusted Book per Share is €1.86. Overall, BeOne Medicines has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Cyclically Adjusted Book per Share compare to MRNA and RPRX?
BeOne Medicines' Cyclically Adjusted Book per Share of €1.86 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Cyclically Adjusted Book per Share is €1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (STU:IJ0) is currently considered Modestly Undervalued. The stock's GF Value™ is €24.51, compared to a current price of €20.57 — trading 16.1% below its estimated fair value. The current Cyclically Adjusted Book per Share is €1.86. BeOne Medicines' overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For BeOne Medicines (STU:IJ0), the current Cyclically Adjusted Book per Share is €1.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (STU:IJ0) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of €20.57 is trading 16.1% below its estimated GF Value™ of €24.51. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for STU:IJ0:

  • Cyclically Adjusted Book per Share: €1.86
  • GF Value™: €24.51 vs. price of €20.57 (16.1% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the STU:IJ0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
83GF Score

Get the complete analysis for STU:IJ0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.57
Price
€24.51
GF Value